Gland Pharma shares jump 12% to 52-week high after strong Q1 show; are key growth challenges over?

Gland Pharma shares surged around 12% after the opening bell on Tuesday, August 11, as investors focused on the company’s strong April to June quarter performance for the financial year 2026-27, amid expectations of key growth challenges nearing an end for the small-cap pharma stock.

NSE data showed that shares of Gland Pharma surged 12% to hit an intraday and 52-week high level of ₹2,987 apiece on Tuesday’s market, in comparison to ₹2,667.30 apiece at the previous stock market close.

After touching the intraday high level in the early market, the pharma stock was trading around ₹2,977 apiece during the trading session on August 11.

With Gland Pharma’s CDMO contract deal in focus, along with the management guidance of a 15% growth in constant currency, experts believe that several key growth challenges for the small-cap pharma stock are now nearing an end.

As per the latest filings, the pharma company’s CDMO business contributed 50% of total revenues, registering a 20% YoY growth in the period under review. Gland Pharma entered into a CDMO partnership with a global pharma company, with the annualised revenue potential estimated at around $90 to $100 million once all products are commercialised.

How did the pharma company perform in Q1?

NSE filings showed that Gland Pharma’s consolidated net profit after tax increased 47% year-on-year (YoY) to ₹317 crore in the April to June quarter of FY27, in comparison to ₹215 crore in the same period of the previous year.

The company’s revenue from core operations advanced 19.5% to ₹1,800 crore in the June quarter results, from ₹1,506 crore in the same period a year earlier, according to the consolidated financial statements.

The revenue growth was largely due to the strong performance in the US market segment, where revenue surged 32% YoY to ₹981 crore, and around 20% in Europe to ₹395 crore.

Gland Pharma’s operational-level earnings before interest, taxes, depreciation, and amortisation (EBITDA) surged 33% YoY to ₹489 crore as compared to ₹368 crore in the corresponding quarter of the previous year.

The company’s EBITDA margins expanded to 27.16% in the June quarter results, in comparison to 24.44% in the same period a year earlier.

The pharma company launched four molecules in the US during the quarter, including multi-vitamin and leucovorin calcium. The company also filed three ANDAs and received seven approvals in the June quarter of FY27.

Are key growth challenges over?

Analysts from leading investment firm Jefferies said that Gland Pharma delivered strong Q1 earnings, beating the earlier estimates, primarily driven by the 32% YoY growth in the company’s key US market.

After the Q1 earnings, the company management has indicated a growth guidance of 15% from its earlier 12-13% levels, indicating better potential and opportunities ahead.

The experts also said that with one major CDMO contract and an in-licensed large TAM differentiated product, many key challenges for Gland are behind it.

“We believe many key challenges for Gland are behind it, with Cenexi breakeven, new contract wins & expansion into complex products,” said Jefferies analysts.

Largely in line with the review, Goldman Sachs analysts also said that amid the management’s growth outlook, the upside potential remains provided the company’s RTU bag line receives approval in the third quarter of FY27.

“Q1 FY27 & reiterated confidence in at least 15% constant-currency growth for FY27, with potential upside if RTU bag line receives approval in Q3 FY27,” said Goldman Sachs analysts.

Focusing on the risk, the experts said that they see certain headwinds to core business margins & potential delays in Cenexi reaching pre-acquisition margins.